Phase III clinical trial for assessment of efficacy and safety of DA-3002 (Recombinant Human Growth Hormone) for prepubertal children with idiopathic short stature in Korea.

Trial Profile

Phase III clinical trial for assessment of efficacy and safety of DA-3002 (Recombinant Human Growth Hormone) for prepubertal children with idiopathic short stature in Korea.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Somatrogon (Primary)
  • Indications Growth disorders; Short stature
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2017 New trial record
    • 04 Nov 2017 Primary endpoint (The difference in annual height velocity (cm/year)) has been met as per the results published in the Journal of Endocrinological Investigation
    • 04 Nov 2017 Results published in the Journal of Endocrinological Investigation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top